Molecular Cancer Therapeutics
Journal metrics
Annual Clarivate and SCImago indicators.
| Year | JCR | SJR | ||||
|---|---|---|---|---|---|---|
| IF | IF quartile | Rank (percentile) | SJR | SJR quartile | Rank (percentile) | |
| 2025 | 6.9 | Q1 | 83.8% | 2.392 | Q1 | 96.6% |
| 2024 | 5.5 | Q1 | 81.9% | 2.493 | Q1 | 96.9% |
| 2023 | 5.3 | Q1 | 78.6% | 2.270 | Q1 | 96.5% |
| 2022 | 5.7 | Q2 | 77.0% | 1.890 | Q1 | 95.3% |
| 2021 | 6.0 | Q2 | 75.6% | 1.831 | Q1 | 95.2% |
| 2020 | — | — | 2.717 | Q1 | 97.4% | |
| 2019 | — | — | 2.463 | Q1 | 96.9% | |
| 2018 | — | — | 2.536 | Q1 | 96.8% | |
Impact history
Annual SJR and Impact Factor trend.
SJRIF
Journal record
eISSN
1538-8514
ISSN
1535-7163
country
UScoverage
2001-2026